Literature DB >> 8152260

Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

J H Gong1, G Maki, H G Klingemann.   

Abstract

The cell line described here was established for a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma whose marrow was diffusely infiltrated with large granular lymphocytes (LGL). Immunophenotyping of marrow blasts and peripheral lymphocytes was positive for CD56, CD2 and CD7, and negative for CD3. Cytotoxicity of peripheral blood mononuclear cells at an effector: target (E:T) cell ratio of 50:1 was 79% against K562 cells and 48% against Daudi cells. To establish the line, cells from the peripheral blood were placed into enriched alpha medium containing 12.5% fetal calf serum, 12.5% horse serum, 10(-4) M beta-mercaptoethanol and 10(-6) M hydrocortisone. Growth of the line (termed NK-92) is dependent on the presence of recombinant IL-2 and a dose as low as 10 U/ml is sufficient to maintain proliferation. Conversely, cells die within 72 h when deprived of IL-2; IL-7 and IL-12 do not maintain long-term growth, although IL-7 induces short-term proliferation measured by 3H-thymidine incorporation. None of the other cytokines tested (IL-1 alpha, IL-6, TNF-alpha, IFN-alpha, IFN-gamma) supported growth of NK-92 cells which have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54, CD56bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34, HLA-DR. DNA analysis showed germline configuration for T-cell receptor beta and gamma genes. CD25 (p55 IL-2 receptor) is expressed on about 50% of all cells when tested at 100 U/ml of IL-2 and its expression correlates inversely with the IL-2 concentration. The p75 IL-2 receptor is expressed on about half of the cells at low density irrespective of the IL-2 concentration. NK-92 cells kill both K562 and Daudi cells very effectively in a 4 h51-chromium release assay (84 and 86% respectively, at an E:T cell ratio of 5:1). The cell line described here thus displays characteristics of activated NK-cells and could be a valuable tool to study their biology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152260

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  229 in total

1.  Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells.

Authors:  Zenggang Pan; Yulei Shen; Cheng Du; Guimei Zhou; Andreas Rosenwald; Louis M Staudt; Timothy C Greiner; Timothy W McKeithan; Wing C Chan
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

2.  Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells.

Authors:  Catharina Gross; Ingo G H Schmidt-Wolf; Srinivas Nagaraj; Robert Gastpar; Joachim Ellwart; Leoni A Kunz-Schughart; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

3.  Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.

Authors:  Roberto Bellucci; Hong-Nam Nguyen; Allison Martin; Stefan Heinrichs; Anna C Schinzel; William C Hahn; Jerome Ritz
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

4.  Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.

Authors:  Jing Chen; Mike Petrus; Bonita R Bryant; Vinh Phuc Nguyen; Carolyn K Goldman; Richard Bamford; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

5.  The Activating C-type Lectin-like Receptor NKp65 Signals through a Hemi-immunoreceptor Tyrosine-based Activation Motif (hemITAM) and Spleen Tyrosine Kinase (Syk).

Authors:  Björn Bauer; Tanja Wotapek; Tobias Zöller; Emilia Rutkowski; Alexander Steinle
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

6.  First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Authors:  Xiaowen Tang; Lin Yang; Zheng Li; Ansel P Nalin; Haiping Dai; Ting Xu; Jia Yin; Fengtao You; Mingqing Zhu; Wenhong Shen; Guanghua Chen; Xiaming Zhu; Depei Wu; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

7.  Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.

Authors:  G S D Reid; S Bharya; H-G Klingemann; K R Schultz
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.

Authors:  Leo L M Poon; Y H Connie Leung; John M Nicholls; Pin-Yu Perera; Jack H Lichy; Masafumi Yamamoto; Thomas A Waldmann; J S Malik Peiris; Liyanage P Perera
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.

Authors:  Sunil S Raikar; Lauren C Fleischer; Robert Moot; Andrew Fedanov; Na Yoon Paik; Kristopher A Knight; Christopher B Doering; H Trent Spencer
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

10.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.